Mio-Aas (Acetylsalicylic Acid)

Mio-Aas belongs to the NSAID class and acts on the cyclo‑oxygenase pathway to relieve several common conditions.

• Pain relief: reduces mild to moderate pain by inhibiting prostaglandin synthesis.
• Fever reduction: lowers elevated body temperature through central thermoregulatory effects.
• Inflammation reduction: diminishes swelling and redness by decreasing inflammatory mediators.
• Prevention of arterial thrombosis: provides antiplatelet activity that lowers the risk of clot formation in cardiovascular disease.

• Acetylsalicylic Acid irreversibly acetylates cyclo‑oxygenase‑1 (COX‑1) and cyclo‑oxygenase‑2 (COX‑2) enzymes, blocking the conversion of arachidonic acid to prostaglandins and thromboxane A2. The resulting reduction in prostaglandins mediates analgesic, antipyretic and anti‑inflammatory effects, while decreased thromboxane A2 limits platelet aggregation and clot formation.

Mio-Aas may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Gastro‑intestinal discomfort: nausea, dyspepsia or heartburn.
• Abdominal pain or mild stomach upset.
• Increased bleeding tendency, such as easy bruising or nosebleeds.
• Skin rash or mild itching.

Serious or Rare Side Effects

• Gastro‑intestinal ulceration or hemorrhage.
• Severe allergic reactions, including anaphylaxis or Stevens‑Johnson syndrome.
• Renal impairment or acute kidney injury.
• Hepatic dysfunction or elevated liver enzymes.
• Reye's syndrome in children following viral illness.

Before using Mio-Aas, consider the following safety measures.

• Assess bleeding risk: avoid in patients with active ulcers or recent surgery.
• Avoid in known aspirin‑sensitive asthma or allergic reactions.
• Use caution in renal impairment: monitor kidney function regularly.
• Monitor in patients taking anticoagulants or other NSAIDs for additive bleeding risk.
• Do not combine with alcohol or other gastric irritants without medical advice.
• Store at ambient temperature: keep in the original pack, protect from moisture.

Mio-Aas can interact with several medication classes; some require avoidance while others need close monitoring.

Major Interactions (Avoid)

• Anticoagulants such as warfarin: increased risk of serious bleeding.
• Other NSAIDs or cyclo‑oxygenase inhibitors: additive gastrointestinal toxicity.
• Corticosteroids: heightened ulcer risk.
• Selective serotonin reuptake inhibitors (SSRIs): enhanced bleeding tendency.
• Lithium: aspirin may raise lithium serum levels.

Moderate Interactions (Monitor Closely)

• ACE inhibitors or ARBs: possible reduction in antihypertensive effect.
• Diuretics: may impair renal function when combined.
• Methotrexate: aspirin can decrease clearance, raising toxicity.
• Oral hypoglycemics: potential alteration of blood glucose control.
• Allopurinol or other uric‑acid‑lowering agents: risk of hypersensitivity reactions.